NFKB1 and cancer: Previous studies have proposed multiple mechanisms of drug resistance in PDAC, including abnormal gene expression, mutations, dysregulation of key signaling pathways (such as NF-κB, Akt and apoptosis-related pathways), EMT and the role of extracellular stromal cells and cancer stem cells [16].